Literature DB >> 20697800

Fragment c gamma receptor gene polymorphisms and breast cancer risk in case-control studies in Japanese, Japanese Brazilians, and non-Japanese Brazilians.

Motoki Iwasaki1, Naoki Shimada, Yoshio Kasuga, Shiro Yokoyama, Hiroshi Onuma, Hideki Nishimura, Ritsu Kusama, Gerson S Hamada, Ines N Nishimoto, Hirofumi Iyeyasu, Juvenal Motola, Fábio M Laginha, Roberto Anzai, Shoichiro Tsugane.   

Abstract

Previous studies showing the presence of antibodies against tumor-associated antigens in healthy individuals suggest that antibody-dependent cell cytotoxicity (ADCC) might play a role in the development of breast cancer. We hypothesized that functional polymorphisms in fragment c gamma receptor (FcgR) genes were associated with breast cancer risk. We conducted hospital-based case-control studies of patients aged 20-74 years with invasive breast cancer, and matched controls from medical checkup examinees in Nagano, Japan and from cancer-free patients in São Paulo, Brazil. A total of 869 pairs (403 Japanese, 80 Japanese Brazilians and 386 non-Japanese Brazilians) were genotyped for two single nucleotide polymorphisms (SNPs): a histidine (H)/arginine (R) polymorphism at position 131 of FcgRIIa (FcgRIIa H131R) and a valine (V)/phenylalanine (F) polymorphism at position 158 of FcgRIIIa (FcgRIIIa F158V). We found no statistically significant association between either of the two SNPs and breast cancer risk regardless of population. In analyses of the three populations combined, adjusted odds ratio (OR) was 0.93 [95% confidence interval (CI) 0.66-1.32] for women with the R/R versus H/H genotype of the FcgRIIa H131R polymorphism and 1.04 (95% CI 0.69-1.57) for the V/V versus F/F genotype of the FcgRIIIa F158V polymorphism. On combination of the two SNPs, compared to women with both the R/R genotype of the FcgRIIa H131R polymorphism and F/F genotype of the FcgRIIIa F158V polymorphism, the adjusted OR for women with both the H/H and V/V genotype was 0.68 (95% CI 0.37-1.27). In conclusion, our findings suggest that ADCC might not play a major role in the etiology of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20697800     DOI: 10.1007/s10549-010-1109-3

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  7 in total

1.  Higher levels of antibodies to the tumour-associated antigen cyclin B1 in cancer-free individuals than in patients with breast cancer.

Authors:  J P Pandey; E Kistner-Griffin; A M Namboodiri; M Iwasaki; Y Kasuga; G S Hamada; S Tsugane
Journal:  Clin Exp Immunol       Date:  2014-10       Impact factor: 4.330

2.  IGHG, IGKC, and FCGR genes and endogenous antibody responses to GARP in patients with breast cancer and matched controls.

Authors:  Janardan P Pandey; Aryan M Namboodiri; Kent E Armeson; Motoki Iwasaki; Yoshio Kasuga; Gerson S Hamada; Shoichiro Tsugane
Journal:  Hum Immunol       Date:  2018-06-04       Impact factor: 2.850

3.  Racially restricted contribution of immunoglobulin Fcγ and Fcγ receptor genotypes to humoral immunity to human epidermal growth factor receptor 2 in breast cancer.

Authors:  J P Pandey; A M Namboodiri; E Kistner-Griffin; M Iwasaki; Y Kasuga; G S Hamada; S Tsugane
Journal:  Clin Exp Immunol       Date:  2013-03       Impact factor: 4.330

4.  Endogenous antibody responses to mucin 1 in a large multiethnic cohort of patients with breast cancer and healthy controls: Role of immunoglobulin and Fcγ receptor genes.

Authors:  Janardan P Pandey; Aryan M Namboodiri; Bethany Wolf; Motoki Iwasaki; Yoshio Kasuga; Gerson S Hamada; Shoichiro Tsugane
Journal:  Immunobiology       Date:  2017-10-18       Impact factor: 3.144

5.  Single-nucleotide polymorphisms and copy number variations of the FCGR2A and FCGR3A genes in healthy Japanese subjects.

Authors:  Hiroyuki Moriya; Katsuhiko Saito; Nuala Helsby; Naomi Hayashi; Shigekazu Sugino; Michiaki Yamakage; Takeru Sawaguchi; Masahiko Takasaki; Masato Takahashi; Nahoko Kurosawa
Journal:  Biomed Rep       Date:  2013-12-06

6.  Genetic variants at 1p11.2 and breast cancer risk: a two-stage study in Chinese women.

Authors:  Yue Jiang; Hao Shen; Xiao'an Liu; Juncheng Dai; Guangfu Jin; Zhenzhen Qin; Jiaping Chen; Shui Wang; Xinru Wang; Zhibin Hu; Hongbing Shen
Journal:  PLoS One       Date:  2011-06-27       Impact factor: 3.240

7.  Fc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatment.

Authors:  Mari Hirvinen; Raita Heiskanen; Minna Oksanen; Saila Pesonen; Ilkka Liikanen; Timo Joensuu; Anna Kanerva; Vincenzo Cerullo; Akseli Hemminki
Journal:  J Transl Med       Date:  2013-08-21       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.